Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The C4 Therapeutics, Inc. (CCCC) SEC filings page on Stock Titan provides structured access to the companys regulatory disclosures as filed with the U.S. Securities and Exchange Commission. C4 Therapeutics is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detail on clinical progress, collaborations, financings and corporate governance related to its targeted protein degradation programs.
Investors can use this page to review Form 8-K current reports in which C4 Therapeutics furnishes quarterly financial results, business highlights and updates on key clinical programs such as cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and non-Hodgkins lymphoma. 8-K filings also document material events including the clinical trial collaboration and supply agreement with Pfizer for elranatamab, underwritten equity offerings involving common stock and warrants, and stockholder approvals to increase authorized shares.
In addition to event-driven 8-Ks, the companys shelf registration statements, prospectus supplements and related exhibits describe the terms of securities offerings used to fund its pipeline, including cemsidomide, CFT8919 and other degrader programs. Governance-related filings, such as amendments to the certificate of incorporation and annual meeting voting results, provide insight into C4 Therapeutics capital structure and board-level decisions.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the most important points in each filing, helping readers quickly understand topics like new clinical data disclosures, changes in collaboration arrangements, or the impact of financings on cash runway. Users interested in CCCC can consult this page to follow how C4 Therapeutics reports its clinical, financial and corporate developments through official SEC channels over time.
C4 Therapeutics Director Utpal Koppikar received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction involved:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a Board member through the vesting date. This grant appears to be part of the company's director compensation program. The transaction was reported by attorney-in-fact Jolie M. Siegel on June 20, 2025.
C4 Therapeutics Director Owen Hughes received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting schedule: Full vesting upon earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting conditions require continued service as a board member, aligning the director's interests with long-term shareholder value. The transaction was executed under direct ownership, with attorney Jolie M. Siegel signing as the authorized representative.
C4 Therapeutics director Stephen Fawell received a stock option grant on June 18, 2025, representing a significant insider transaction. The derivative securities transaction details include:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
This Form 4 filing indicates standard board compensation practices through equity grants. The vesting structure aligns with typical director compensation arrangements, requiring continued board service. The relatively low exercise price suggests the company's stock may have experienced recent price declines, as C4 Therapeutics focuses on targeted protein degradation for treating cancer and other diseases.
C4 Therapeutics director Kenneth Carl Anderson received a stock option grant on June 18, 2025. The derivative security details include:
- Granted 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The grant represents standard director compensation, with vesting contingent on continued board service. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025. This Form 4 disclosure complies with SEC requirements for reporting changes in beneficial ownership by company insiders.
C4 Therapeutics (NASDAQ:CCCC) filed a routine Form 4 on June 28, 2025, reporting that director Laura Bessen received a grant of 35,500 stock options on June 18, 2025 at an exercise price of $1.44 per share.
The options vest in full on the earlier of June 18, 2026 or the company’s next annual stockholder meeting, provided she remains on the board. No shares were sold, and the transaction reflects standard board compensation rather than an open-market trade. After the grant, Bessen directly holds 35,500 derivative securities.
C4 Therapeutics director Donna Roy Grogan received a stock option grant on June 18, 2025, as reported in a Form 4 filing. The derivative securities transaction details include:
- Grant of 35,500 stock options to purchase common stock
- Exercise price set at $1.44 per share
- Options expire on June 17, 2035
- Vesting occurs at earlier of June 18, 2026 or next annual stockholder meeting
The options are subject to continued service as a board member. This grant represents standard non-employee director compensation. The filing was signed by attorney-in-fact Jolie M. Siegel on June 20, 2025.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
